Antibiotics: the changing regulatory and pharmaceutical – publication

Antibiotics: the changing regulatory and pharmaceutical – published Journal of Antimicrobial Chemotherapy, January 2015

Abstract: Drug licensing is changing. Previously, regulators prioritized the licensing of innovative drugs that fulfilled a high unmet medical need for a small number of patients, including orphan, cancer and HIV medicines. Alternatives to large and costly prospective, randomized, double-blind clinical trials have led to a more bespoke development, such as adaptive design studies. Regulators have recently agreed to include much-needed narrow-spectrum antibiotics, active against certain MDR bacteria, in this paradigm. The background to why big pharmaceutical companies have largely deserted the antibacterial research arena, and the proposals that are hoped to reinvigorate their interest, are presented.

Click here to access the the publication.

Back to Resources

Share thisShare on FacebookTweet about this on TwitterEmail this to someone
The British Society for Antimicrobial Chemotherapy (BSAC)
© 2017 Registered Charity 1093118.

Registered as a company limited by guarantee in England & Wales No: 4443910

By using this site, you agree to using cookies.
For more details about cookies and how to disable them, see resource here >
Top